Copyright
©The Author(s) 2020.
World J Hepatol. Apr 27, 2020; 12(4): 116-124
Published online Apr 27, 2020. doi: 10.4254/wjh.v12.i4.116
Published online Apr 27, 2020. doi: 10.4254/wjh.v12.i4.116
Table 1 Overall and regional primary sclerosing cholangitis clinical outcomes in terms of overall survival (measured in years) and incidence of cholangiocarcinoma
| Region | Studies (n) | Total patients (n) | Age at diagnosis (yr) | PSC-IBD co-incidence (%) | Transplant free survival (yr) | Overall survival (yr) | Time to LT (yr) | Annual incidence CCA1 |
| Africa | 0 | 0 | - | - | - | - | - | - |
| Asia | 9 | 711 | 39 | 39% | 20.8 | 23.6 | 3.5 | 1503 |
| Europe | 18 | 3993 | 35 | 74% | 17.3 | 14.8 | 4.9 | 303 |
| North America | 14 | 1155 | 31 | 66% | 14.5 | 13.8 | 3 | 642 |
| South America | 1 | 21 | 7 | 24% | - | - | - | 433 |
| Oceania | 4 | 416 | 47 | 79% | 23.3 | 10 | 8 | 439 |
| International | 1 | 7121 | 39 | 73% | 14.5 | - | - | - |
| Overall | 47 | 13417 | 37 | 71% | 15.9 | 15.3 | 4.6 | 500 |
- Citation: Mehta TI, Weissman S, Fung BM, Tabibian JH. Geoepidemiologic variation in outcomes of primary sclerosing cholangitis. World J Hepatol 2020; 12(4): 116-124
- URL: https://www.wjgnet.com/1948-5182/full/v12/i4/116.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i4.116